目的 探討小兒咳喘靈顆粒聯(lián)合頭孢他啶治療兒童支原體肺炎的臨床療效。方法 選取2021年8月—2023年8月北京市大興區(qū)人民醫(yī)院收治的116例支原體肺炎患兒，按隨機(jī)數(shù)字表法將所有患兒分為對(duì)照組和治療組，每組各58例。對(duì)照組靜脈滴注注射用頭孢他啶，50 mg/(kg∙次)，加入5%葡萄糖注射液100 mL中稀釋后使用，2次/d。治療組在對(duì)照組治療基礎(chǔ)上開水沖服小兒咳喘靈顆粒，患兒年齡≤2歲，1 g/次；2歲＜患兒年齡≤4歲，1.5 g/次；4歲＜患兒年齡≤7歲，2 g/次；7歲＜患兒年齡≤11歲，2.5 g/次；11歲＜患兒年齡≤14歲，3 g/次，3次/d。兩組療程7 d。觀察兩組臨床療效、主癥消失時(shí)間、肺炎支原體IgM抗體（MP-IgM）轉(zhuǎn)陰率；比較治療前后兩組全血血小板與淋巴細(xì)胞比值（PLR）、血清C反應(yīng)蛋白（CRP）水平。結(jié)果 治療后，治療組總有效率是96.55%，顯著高于對(duì)照組的86.21%（P＜0.05）。治療過程中，治療組發(fā)熱、咳嗽、氣喘、痰壅、肺部啰音消失時(shí)間顯著短于對(duì)照組（P＜0.05）；治療組MP-IgM轉(zhuǎn)陰率是89.66%，顯著高于對(duì)照組75.86%（P＜0.05）。治療后，兩組全血PLR和血清CRP水平低于同組治療前（P＜0.05）；治療后，治療組全血PLR和血清CRP水平低于對(duì)照組（P＜0.05）。結(jié)論 小兒咳喘靈顆粒聯(lián)合頭孢他啶治療兒童支原體肺炎具有較好的臨床療效，能有效控制支原體感染，抑制炎癥反應(yīng)，加速癥狀的緩解，值得臨床推廣應(yīng)用。

Objective To explore the clinical efficacy of Xiao’er Kechuanling Granules combined with ceftazidime in treatment of mycoplasma pneumonia in children. Methods A total of 116 children with mycoplasma pneumonia admitted to Beijing Daxing District People’s Hospital from August 2021 to August 2023 were selected and divided into control group and treatment group according to random number table method, with 58 cases in each group. Patients in the control group were iv administered with Ceftazidime for injection, 50 mg/(kg∙time), diluted with 5% glucose injection 100 mL, twice daily. Patients in the treatment group were po administered with Xiao’er Kechuanling Granules on the basis of the control group, children ≤ 2 years old, 1 g/ time, children < 2 years old ≤ 4 years old, 1.5 g/ time, children < 4 years old ≤ 7 years old, 2 g/ time, children < 7 years old ≤ 11 years old, 2.5 g/ time, children < 11 years old ≤ 14 years old, 3 g/ time, 3 times daily. Both groups were treated for 7 d. The clinical efficacy, the time of disappearance of main symptoms and the negative conversion rate of mycoplasma pneumoniae IgM antibody (MP-IgM) were observed in the two groups. Whole blood platelet-lymphocyte ratio (PLR) and serum C-reactive protein (CRP) levels were compared between the two groups before and after treatment. Results After treatment, the total effective rate of the treatment group was 96.55%, significantly higher than that of the control group (86.21%, P < 0.05). In the course of treatment, the disappearance times of main symptoms (fever, cough, asthma, phlegm obstruction, and pulmonary rales) in the treatment group was significantly shorter than that in the control group (P < 0.05). The negative conversion rate of MP-IgM in the treatment group was 89.66%, which was significantly higher than 75.86% in the control group (P < 0.05). After treatment, whole blood PLR and serum CRP levels in two groups were lower than before treatment (P < 0.05). After treatment, the levels of whole blood PLR and serum CRP in treatment group were lower than those in control group (P < 0.05). Conclusion Xiao’er Kechuanling Granules combined with ceftazidime has good clinical efficacy in treatment of mycoplasma pneumonia in children, and can effectively control mycoplasma infection, inhibit inflammation, accelerate the relief of symptoms, which is worthy of clinical application.

R974;R985